A double-blind placebo-controlled clinical trial of botulinum toxin type A injection therapy in patients with Japanese cedar pollinosis 2010

A double-blind placebo-controlled clinical trial of botulinum toxin type A injection therapy in patients with Japanese cedar pollinosis 2010 - Effect of Botrinum Toxin Type A Therapy in Patients with Japanese cedar pollinosis (E-BOAT study 2)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003065

Enrollment

Registered

2010-01-25

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

One ml (20U) of botulinum toxin type A is injecjected into each inferior turbinate just before the beggining of pollen scattering. Loratadine (10mg)and/or Betamethasone/d-Chlorpheniramine Maleate can

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) a history of Japanese cedar pollinosis 2) CAP-RAST aginst Jananese cedar pollen >=2

Exclusion criteria

Exclusion criteria: 1) pregnancy or possibility of pregnancy 2) history of heart desease 3) history of glaucoma 4) history of prostate hypertrophy 5) history of neuro-muscular desiases 6) history of stroke 7) accampanying acute rhinitis or sinusitis 8) use of any anti-allergy drugs at the beginning of the study 10) prominent deviation of the nasal septum

Design outcomes

Primary

Measure	Time frame
Symptom score, Medication score, QOL estimation, rhinomanometry	—

Secondary

Measure	Time frame
adverse events	—

Countries

Japan

Contacts

Public ContactAtsushi Kamijo

University of Yamanashi Department of Otorhinolaryngoloty, Head and Neck Surgery

akamijyo@yamanashi.ac.jp055-273-6769

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026